PTO/SB/08e (06-03) Approved for use through 07/31/2003, OMB 0851-0031 U.S. Petent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE Panenwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number C mpl te if Known titute for form 1449A/PTO Application Number 09/425,804 Filing Date October 25,1999 INFORMATION DISCLOSURE Gorenstein, et al. First Named Inventor STATEMENT BY APPLICANT 1634 Art Unit Examiner Name Zitomer, Stephanie W. (Use se many sheets as necessary)

Attorney Docket No.

UTMB:1001

AUG 1 2 2003

E THENEND

Sheet

			U.S. PATENT D		
Exeminer Intitials*	Cite No.1	Document Number Number-Kind Code ^{2 (it sey)}	Publication Date MM-DD-YYYY	Names of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
SZ		US-5,660,985 A	August 28, 1997	KIRSCHENHEUTER, GARY P.,	Entire Document
		US-			
		U\$-			
·		US-			
	 	US-			
	T	US-			
	1	us-			
	1	US-			
	1	US-			
<u> </u>	 	U\$-			
	1	US-			
	1	US-			
····	1	US-			
	†	US-			
	1	US-			
	 	US-		 	
	1	I	FOREIGN PATENT	DOCUMENTS	<u> </u>
xeminer	CHe	ForeignPatent Document	Publication Date	Namesof Patentee or	Pages Columns, Lines, Where
ntitiele	No.1	WO 92 14842 A	MM-DD-YYYY	Applicant of Cited Document	Relevant Passegusor Relevant
32	 		September 3, 1992	GILEAD SCIENCES, INC.	Claims 1, 11
		WO 93 08298 A	April 29, 1993	ISIS PHARM ACEUTICALS, INC.	Claims 14, 26
<u> </u>	1	WO 96 19572 A	June 27, 1996	HYBRIDON, INC; TANG JINYAN (US); ROSKEY	Entire Document

Examiner	0 7,	Date	0
Signature	J. Homer	Considered	17-10-02
4500000000	Z IONE		1 10 0 3

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. § Applicant's unique citation designation number (optional). § See Kinds Codes of USPO Patent Documents at www.utsplo.gov or MPEP 901.04. § Enter Office that issued the document, by the two-tester code (WIPO Standard ST.3). § For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. § Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. § Applicant is to place a check mark here if English language.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandris, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND T: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/086 (06-03) Approved for use through 06/30/2003. OMB 0651-0031 U.S. Patent and Tradomark Office; U.S. DEPARTMENT OF COMMERCE

he Paperwork Reduction Act of 1995, no porsons are required to respond to a collection of information unless a contains a valid OMB control number.

RADE Mule for form 14498/PTO

AUS 1 2 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	4

Complete If Known					
Application Number	09/425,804				
Filing Date	October 25,1999				
First Named Inventor	Gorenstein, et al.				
Art Unit	1634.00				
Examiner Name	Zitomer, Stephanie W.				
Attorney Docket No.	UTMB:1001				

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.5	includename of the author (In CAPITALLETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-lasus number(s), published.					
SZ	The second secon	BIELINSKA A ET AL: "REGULATION OF GENE EXPRESSION WITH DOUBLE-STRANDED PHOSPHOROTHIOATE OLIGONUCLEOTIDES" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 250, 16 November 1990 (1990-11-16), pages 997-1000, XP002065516 ISSN: 0036-8075	the second section of the second section of				
		KUNSCH, CHARLES ET AL: "Selection of optimal.kappa.B/Rel DNA-binding motifs: interaction of bot subunits of NFkappa.B with DNA is required for transcriptional activation" MOLECULAR AND CELLULAR BIOLOGY (1992), 12(10), 4412 -2, XP009003474	and the second of the second o				
	A CAMPACIAN AND A COMMAN AND THE ABOUT THE ABO	ANTSYPOVICH, SERGEI ET AL: "Cross-linked DNA duplexes. Exonuclease stability and interactio with the nucleic transcription factor of the kappa. light-chai enhancer (NF-, kappa. B)" EUROPEAN JOURNAL OF BIOCHEMISTRY (1998), 255(2), 414-421, xp002226148	The second secon				

. I		_	a
Examiner	J. Cutoner	Date	1 7-10-01
Signature		Considered	1 100
(0013106160	<u> </u>

^{*}EXAMINER: Initial II reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

considered. Include copy of this form with next communication to epplicant.

1 Applicants unique citation designation number (optional). 2 Applicants a check mark here if English tanguage Translation is ettached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a bornefit by the public which is to site (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this buffen, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, OP NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (06-03)
Approved for use through 06/30/2003. OMB 0651-0031
U.S. Patent and Tradgmark Office; U.S. DEPARTMENT OF COMMERCE

AUG 1 2 2003

011 5

erwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Pa

Company Stor to	rm 1449B/PTO			Complete If Known		
				Application Number	09/425,804	
	MATION DI			Filing Date	October 25,1999	
STATE	MENT BY	APPLI	CANT	First Named Inventor	Gorenstein, et al.	
				Art Unit	1634.00	
(Use as many sheets as necessary)				Examiner Name	Zitomer, Stephanie W.	
Sheel		- 01		Attorney Docket No.	1 DVB-1001	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-listue number city and/or country where published.					
SZ		STEC, W.J. ET AL.: "Deoxyribonucleoside 3'-O-(2-thio- and 2-oxo-"spiro"-4,4-pentamethylene-1,3,2-oxa thiaphospholane)s" J. AM.CHEM. SOC., vol. 120, 1998, pages 7156-7167, XP002239290	e demonstrate la confederación de contrata manifesta es en el contrata de la contrata del contrata del contrata de la contrata del la contrata de la contrata del la contrata de la contra			
		UHLMANN E ET AL: "STUDIES ON THE MECHANISM OF STABILIZATION OF PARTIALLY PHOSPHOROTHIOATED OLIGONUCLEOTIDES AGAINST NUCLEOLYTIC DEGRADATION" ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, MARY ANN LIEBERT, INC., NEW YORK, US, vol. 7, no. 4, August 1997 (1997-08), pages 345-350, XP001117604 ISSN: 1087-2906	THE RECEIVED A PROPERTY OF THE			
		NAKAMAYE, KAY L. ET AL: "Direct sequencing of polymerase chain reaction amplified DNA fragments through the incorporation of deoxynucleoside.alpha.—thiotriphosphates" NUCLEIC ACIDS RESEARCH (1988), 16(21), 9947-59, 1988, XP001097564	a capper of a second of the se			

		7	-
Examiner	S- Litomer	Date	945-63
Signature		Considered	17005

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or rotain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of little you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. B x 1450, Alexandria, VA 22313-1450.